The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

Puneet Puri, Kalyani Daita, Andrew Joyce, Faridoddin Mirshahi, Prasanna K. Santhekadur, Sophie Cazanave, Velimir A Luketic, Mohammad S. Siddiqui, Sherry Boyett, Hae‐Ki Min, Divya P. Kumar, Rohit Kohli, Huiping Zhou, Phillip B. Hylemon, Melissa J. Contos, Michael Idowu, Arun J. Sanyal – 11 July 2017 – The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% of NASH patients. Bile acids (BA) are linked to the pathogenesis and therapy of NASH.

The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids

Puneet Puri, Kalyani Daita, Andrew Joyce, Faridoddin Mirshahi, Prasanna K. Santhekadur, Sophie Cazanave, Velimir A Luketic, Mohammad S. Siddiqui, Sherry Boyett, Hae‐Ki Min, Divya P. Kumar, Rohit Kohli, Huiping Zhou, Phillip B. Hylemon, Melissa J. Contos, Michael Idowu, Arun J. Sanyal – 11 July 2017 – The histologic spectrum of nonalcoholic fatty liver disease (NAFLD) includes fatty liver (NAFL) and steatohepatitis (NASH), which can progress to cirrhosis in up to 20% of NASH patients. Bile acids (BA) are linked to the pathogenesis and therapy of NASH.

Ethanol‐induced steatosis involves impairment of lipophagy, associated with reduced Dynamin2 activity

Karuna Rasineni, Terrence M. Donohue, Paul G. Thomes, Li Yang, Dean J. Tuma, Mark A. McNiven, Carol A. Casey – 10 July 2017 – Lipid droplets (LDs), the organelles central to alcoholic steatosis, are broken down by lipophagy, a specialized form of autophagy. Here, we hypothesize that ethanol administration retards lipophagy by down‐regulating dynamin 2 (Dyn2), a protein that facilitates lysosome re‐formation, contributing to hepatocellular steatosis. Primary hepatocytes were isolated from male Wistar rats fed Lieber–DeCarli control or ethanol (EtOH) liquid diets for 6‐8 weeks.

Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen–positive graft

Shih‐Ho Wang, Poh‐Yen Loh, Ting‐Lung Lin, Li‐Man Lin, Wei‐Feng Li, Yu‐Hung Lin, Chih‐Che Lin, Chao‐Long Chen – 10 July 2017 – De novo hepatitis B virus (DNHB) infections may occur in recipients who do not receive prophylaxis after liver transplantation (LT) with antibody to hepatitis B core antigen (anti‐HBc)–positive donor grafts. Active immunization has been shown to prevent DNHB in pediatric recipients. Our aim is to investigate the efficacy of HBV vaccination for preventing DNHB in adult living donor liver transplantation (LDLT).

Critical care management of the patient with cirrhosis awaiting liver transplant in the intensive care unit

Jody C. Olson, Constantine J. Karvellas – 8 July 2017 – Patients with cirrhosis who are awaiting liver transplantation (LT) are at high risk for developing critical illnesses. Current liver allocation policies that dictate a “sickest first” approach coupled with a mismatch between need and availability of organs result in longer wait times, and thus, patients are becoming increasingly ill while awaiting organ transplantation.

Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure

David Wyles, Heiner Wedemeyer, Ziv Ben‐Ari, Edward J. Gane, Jesper Bach Hansen, Ira M. Jacobson, Alex L. Laursen, Annie Luetkemeyer, Ronald Nahass, Stephen Pianko, Stefan Zeuzem, Patricia Jumes, Hsueh‐Cheng Huang, Joan Butterton, Michael Robertson, Janice Wahl, Eliav Barr, Hee‐Koung Joeng, Elizabeth Martin, Lawrence Serfaty, for the C‐CREST Part C and C‐SURGE Investigators – 7 July 2017 – People with hepatitis C virus (HCV) infection who have failed treatment with an all‐oral regimen represent a challenging treatment population.

Subscribe to